00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Public markets are reopening for biotech companies after years of muted activity,
00:06but the strongest firms may still opt to sell to Big Pharma, rather than pursue an IPO,
00:11according to CNBC. Investors are far more selective than during the pandemic era boom,
00:17and many biotech companies are now running dual-track processes,
00:21preparing for an IPO while simultaneously engaging with potential acquirers.
00:25Big Pharma buyers are well-funded and willing to take larger bets to replenish pipelines
00:29ahead of major patent expirations later this decade.
00:32In 2025, seven biopharma deals were valued between $5 billion and $15 billion.
00:39Nearly halfway through 2026, six deals in that range have already closed,
00:43putting the year on pace to surpass 2025's total of seven such deals.
00:48For all things money, visit Benzinga.com.
Comments